Diagnostic and therapeutic endoscopy

Journal of Surgical Oncology

Volumn 92, Issue 3, 2005, Pages 203-209

  Kuipers, E J ^a   Haringsma, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Barretts esophagus; Endoscopic mucosal resection; Endoscopy; Esophageal adenocarcinoma; Fluorescence endoscopy; Magnifying endoscopy; Photodynamic therapy; Stent

Indexed keywords

AMINOLEVULINIC ACID; PHOTOFRIN; PHOTOSENSITIZING AGENT;

ADVANCED CANCER; ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; CHROMOENDOSCOPY; CLINICAL PRACTICE; CYTOLOGY; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC THERAPY; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; FLUORESCENCE; HISTOLOGY; HUMAN; OPTICS; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STENT;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; MUCOUS MEMBRANE; PHOTOCHEMOTHERAPY;

EID: 28844506378     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20361     Document Type: Review

References (35)

1. McColl KE: When saliva meets acid: Chemical warfare at the oesophagogastric junction. Gut 2005;54:1-3.
2. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-146.
3. van Soest E, Dieleman J, Siersema PD, et al.: Increasing Incidence of Barrett's Esophagus in the General Population. Gut 2005;54:1062-1066.
4. Klinkenberg-Knol EC, Nelis F, Dent J, et al.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety and influence on gastric mucosa. Gastroenterology 2000;118:661-669.
5. Sharma P, McQuaid K, Dent J, et al.: A critical review of the diagnosis and management of Barrett's esophagus: The AGA Chicago Workshop. Gastroenterology 2004;127:310-330.
6. Eloubeidi MA, Provenzale D: Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy. Am J Gastroenterol 1999;94:937-943.
7. Cooper GS, Yuan Z, Chak A, et al.: Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia. Cancer 2002;95:32-38.
8. Corley DA, Levin TR, Habel LA, et al.: Surveillance and survival in Barrett's adenocarcinomas: A population-based study. Gastroenterology 2002;122:633-640.
9. Sampliner RE and the Practice Parameters Committee of the American College of Gastroenterology: Updated guidelines for the diagnosis, surveillance, and management of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-1895.
10. Armstrong D, Marshall JK, Chiba N, et al.: Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults- update 2004. Can J Gastroenterol 2005;19:15-35.
11. Streitz JM, Jr Andrews CW, Jr, Ellis FH, Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993;105:383-387.
12. van Sandick JW, van Lanschot JJ, Kuiken BW, et al.: Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-222.
13. Anderson LA, Murray LJ, Murphy SJ, et al.: Mortality in Barrett's oesophagus: Results from a population based study. Gut 2003;52:1081-1084.
14. van den Burgh A, Dees J, Hop WC, et al.: Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
15. Kuipers EJ: Review article: Exploring the link between Helicobacter pylori and gastric cancer. Aliment Pharmacol Ther 1999;13:3-12.
16. Eliakim R, Yassin K, Shlomi I, et al.: A novel diagnostic tool for detecting oesophageal pathology: The PillCam oesophageal video capsule. Aliment Pharmacol Ther 2004;20:1083-1089.
17. Faulx AL, Catanzaro AT, Zyzanski S, et al.: Patient tolerance and acceptability of unsedated ultrathin esophagoscopy. Gastrointest Endosc 2002;55:620-623.
18. Nietert PJ, Silverstein MD, Mokhashi MS, et al.: Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc 2003;57:311-318.
19. Canto MI, Setrakian S, Willis J, et al.: Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gastrointest Endosc 2000;51:560-568.
20. Wo JM, Ray MB, Mayfield-Stokes S, et al.: Comparison of methylene blue-directed biopsies and conventional biopsies in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus: A preliminary study. Gastrointest Endosc 2001;54: 294-301.
21. Kiesslich R, Neurath MF, Galle PR: Chromoendoscopy and magnifying endoscopy in patients with gastroesophageal reflux disease. Useful or negligible? Dig Dis 2004;22:142-147.
22. Sharma P, Weston AP, Topalovski M, et al.: Magnification chromendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. Gut 2003;52:24-27.
23. Endo T, Awakawa T, Takahashi H, et al.: Classification of Barrett's epithelium by magnifying endoscopy. Gastrointest Endosc 2002; 55:641-647.
24. Guelrud M, Herrera I, Essenfeld H, et al.: Enhanced magnification endoscopy: A new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 2001;53:559-565.
25. Meining A, Rosch T, Kiesslich R, et al.: Inter- and intra-observer variability of magnification chromoendoscopy for detecting specialized intestinal metaplasia at the gastroesophageal junction. Endoscopy 2004;36:160-164.
26. Yoshida T, Inoue H, Usui S, et al.: Narrow-band imaging system with magnifying endoscopy for superficial esophageal lesions. Gastrointest Endosc 2004;59:288-295.
27. Haringsma J, Tytgat GN, Yano H, et al.: Autofluorescence endoscopy: Feasibility of detection of GI neoplasms unapparent to white light endoscopy with an evolving technology. Gastrointest Endosc 2001;53:642-650.
28. Rabinovitch PS, Longton G, Blount PL, et al.: Predictors of progression in Barrett's esophagus III: Baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071-3083.
29. Vieth M, Ell C, Gossner L, et al.: Histological analysis of endoscopic resection specimens from 326 patients with Barrett's esophagus and early neoplasia. Endoscopy 2004;36:776-781.
30. Buskens CJ, Westerterp M, Lagarde SM, et al.: Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc 2004;60:703-710.
31. Overholt BF, Panjehpour M, Halberg DL: Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: Long-term results. Gastrointest Endosc 2003;58:183-188.
32. Hinnen P, de Rooij FW, Terlouw EM, et al.: Porphyrin biosynthesis in human Barrett's oesophagus and adenocarcinoma after ingestion of 5-aminolaevulinic acid. Br J Cancer 2000;83:539-543.
33. Hage M, Siersema PD, van Dekken H, et al.: 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: A randomised trial. Gut 2004; 53:785-790.
34. Hage M, Siersema PD, Vissers KJ, et al.: Molecular evaluation of ablative therapy of Barrett's oesophagus. J Pathol 2005;205: 57-64.
35. Ell C, May A, Gossner L, et al.: Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000;118:670-677.